Lamivudine: A review of its therapeutic potential in chronic hepatitis B

Drugs

Volumn 58, Issue 1, 1999, Pages 101-141

  Jarvis, Blair ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hepatitis B; Lamivudine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PENCICLOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; CHILL; CHINESE; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; FATIGUE; FEVER; HAIR LOSS; HEADACHE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALAISE; MYALGIA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; REINFECTION; REVIEW; SIDE EFFECT; VERTIGO; VIRUS REPLICATION; VOMITING;

ANIMALS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032783736     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958010-00015     Document Type: Review

References (279)

1. 1. Nassal M, Schaller H. Hepatitis B virus replication an update. J Viral Hepatitis 1996; 3: 217-26
2. 2. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 1406-39
3. 3. Yokosuka O, Omata M, Imazeki F, et al. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315: 1187-92
4. 4. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998; 339 (2): 114-5
5. 5. Beasley RP. Hepatitis B virus the major etiology of hepatocellular carcinoma. Cancer 1988 May 15; 61 (10): 1942-56
6. 6. Idilman R, De Maria N, Colantoni A, et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepatitis 1998; 5: 285-99
7. 7. Leon R, de Medina M, Schiff ER. Diagnostic tools in the evaluation of patients with viral hepatitis undergoing liver transplantation. Liver Transpl Surg 1998; 4: 94-103
8. 8. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepatitis 1997; 4: 1-8
9. 9. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997 Aug; 43 Pt 2: 1500-6
10. 10. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 Dec 11; 337: 1733-45
11. 11. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994 Sep; 23 (3): 437-55
12. 12. Scheuer PJ, Davies SE, Dhillon AP. Histopathological aspects of viral hepatitis. J Viral Hepatitis 1996; 3: 277-83
13. 13. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996 Apr 30; 93: 4398-402
14. 14. Zeuzem S, de Man RA, Honkoop P, et al. Dynamics of hepatitis B infection in vivo. J Hepatol 1997; 27: 431-6
15. 15. Wang P, Hong JH, Cooperwood JS, et al. Recent advances in L-nucleosides: chemistry and biology. Antiviral Res 1998; 40: 19-44
16. 16. Palmer S, Cox S. Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother 1997 Feb; 41: 460-4
17. 17. Chang CN, Skalski V, Zhou JH, et al. Biochemical pharmacology of (+) and (-)-2′,3′-dideoxy-3′-thiacytidine as antihepatitis B-virus agents. J Biol Chem 1992 Nov 5; 267: 22414-20
18. 18. Rahn JJ, Kieller DM, Tyrrell DLJ, et al. Modulation of the metabolism of β-L-(-)-2′,3′-dideoxy-3′-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother 1997 May; 41: 918-23
19. 19. Johnson MA, Moore KHP, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66
20. 20. Doong S L, Tsai C-H, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 8495-9
21. 21. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996 May; 40: 1282-4
22. 22. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol 1995 Mar; 22: 263-7
23. 23. Xie H, Voronkov M, Liotta DC, et al. Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. Antiviral Res 1995 Oct; 28: 113-20
24. 24. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl-]cytosine. Antimicrob Agents Chemother 1992; 36: 2686-92
25. 25. Chang C-N, Doong S-L, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 207 (20): 13938-42
26. 26. Perigaud C, Gosselin G, Girardet J-L, et al. The 5-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part 1. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir. Antiviral Res 1999; 40: 167-78
27. 27. Zembower DE, Lin Y-M, Flavin MT, et al. Robustaflavone, a potential non-nucleoside anti-hepatitis B agent. Antiviral Res 1998; 39: 81-8
28. 28. King RW, Ladner SK, Miller TJ, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1998; 42: 3179-86
29. 29. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995 Jan; 29: 49-51
30. 30. Han E, Burakova T, Dagan S, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999; 29: 553-62
31. 31. Niesters HGM, de Man RA, Haagsma E. Treatment of hepatitis B virus infection after liver transplantation: risk for selection of viral mutants [abstract]. Eur J Gastroenterol Hepatol 1997 Dec; 9: A11-2
32. 32. Wright T, Perrillo R, Rakela J, et al. Lamivudine treatment of hepatitis B virus infection before and after orthotopic liver transplantation [abstract]. J Gastroenterol Hepatol 1997 Dec; 12 Suppl. 1: A192
33. 33. Petit MA, Buffellu D, Saurini F, et al. Residual hepatitis B virus (HBV) infection in liver transplant patients under treatment with lamivudine (3TC) [abstract no. 65]. Gastroenterol Clin Biol 1997 Oct; 21
34. 34. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 Sep; 24: 711-3
35. 35. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 Sep; 24: 714-7
36. 36. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 Jan 4; 349: 20-2
37. 37. Naoumov NV, Chokshi S, Smith HM, et al. Emergence and characterization of lamivudine-resistant hepatitis B virus variant [abstract no. 621]. Hepatology 1996 Oct; 24 (Pt 2): 282A
38. 38. Honkoop P, Niesters HGM, de Man RAM, et al. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997 Jun; 26: 1393-5
39. 39. Naoumov NV, Perrillo RP, Chokshi S, et al. Reduction in hepatitis B virus quasispecies during lamivudine treatment is associated with enhanced virus replication and hepatocytolysis [abstract no. 885]. Hepatology 1995 Oct; 22 (Pt 2): 328A
40. 40. Niesters HGM, Honkoop P, Haagsma EB, et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998 May; 177: 1382-5
41. 41. Buti M, Jardi R, Cotrina M, et al. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998 Mar; 28: 510-3
42. 42. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7
43. 43. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-6
44. 44. Lai CL, Liaw YF, Leung NWY, et al. Genotypic resistance to lamivudine in a prospective placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters [abstract no. 522]. Hepatology 1997; 26 (4) Pt 2: 259A
45. 45. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339 (2): 61-8
46. 46. Marzano A, Debernardi-Venon W, Condreay L, et al. Efficacy of lamivudine re-treatment in a patient with hepatitis B virus (HBV) recurrence after liver transplantation and HBV-DNA breakthrough during the first treatment. Transplantation 1998 Jun 15; 65 (11): 1499-500
47. 47. Honkoop P, de Man RA, Niesters HGM, et al. Incidence, characteristics and clinical impact of lamivudine resistance in chronic hepatitis B [abstract no. GS4/25]. J Hepatol 1998; 28 Suppl. 1: 48
48. 48. Whalley S, Manolakopoulos S, Brown D, et al. Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pretreatment viral load in patients with chronic infection [abstract no. P/C06/014]. J Hepatol 1998; 28 Suppl. 1: 111
49. 49. Wolters LMM, Honkoop P, de Man RA, et al. Famciclovir treatment in lamivudine resistent chronic hepatitis B patients [abstract no. P/C06/024]. J Hepatol 1998; 28 Suppl. 1: 113
50. 50. Goffin E, Horsmans Y, Cornu C. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998 Aug 15; 66: 407-9
51. 51. Honkoop P, de Man RA, Niesters HGM, et al. Clinical impact of lamivudine resistance in chronic hepatitis B [letter]. J Hepatol 1998; 29: 510-1
52. 52. de Man RA, Bartholomeusz AI, Niesters HGM, et al. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 669-75
53. 53. Shields PL, Ling R, Harrison T, et al. Management and outcome of lamivudine (LAM)-Resistant hepatitis B virus (HBV) infection after liver transplantation [abstract no. 527]. Hepatology 1997 Oct; 26 (Pt 2): 260A
54. 54. Lau DTY, Ghany MG, Doo E, et al. Features of response and resistance to lamivudine in patients with chronic hepatitis B with and without HBeAg [abstract no. 623]. Hepatology 1998 Oct; 28 (4 Pt 2): 318A
55. 55. Schinazi RF, Van Gevt C, Stang H, et al. Dynamics of emergence and disappearance of antiviral drug-associated mutations in hepatitis B virus [abstract no. 1305]. Hepatology 1998 Oct; 28 (4 Pt 2): 489a
56. 56. Pillay D, Ratsliffe D, Cane P, et al. Effect of lamivudine of HBV/HIV co-infected patients - the emergence of HBV polymerase variants [abstract no. P/C06/024]. J Hepatol 1999; 30 Suppl. 1: 119
57. 57. Ben-Ari Z, Zemel R, Kazetsker A, et al. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Am J Gastroenterol 1999; 94: 663-7
58. 58. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715-21
59. 59. Tillmann HL, Trautwein C, Bock T, et al. Treatment with lamivudine in relation to response under famciclovir and viral mutations [abstract no. P/C01/019]. J Hepatol 1999; 30 Suppl. 1: 77
60. 60. Cotrina M, Buti M, Jardí R, et al. Resistance to lamivudine in patients with chronic hepatitis B with and without HBeAg [abstract no. P/C06/029]. J Hepatol 1999; 30 Suppl. 1: 121
61. 61. Landau A, Pialoux G, Batisse D, et al. Hepatitis B escape mutant in HBV and HIV coinfected patients receiving multitherapy including lamivudine [abstract no. C06/011]. J Hepatol 1999; 30 Suppl. 1: 232
62. 62. Rey D, Fritsch S, Labouret N, et al. A study of HBV resistance to lamivudine therapy in HBV and HIV coinfected patients [abstract no. C06/039]. J Hepatol 1999; 30 Suppl. 1: 239
63. 63. Torre F, Campo N, Dardano F, et al. Longitudinal analysis of the appearance of lamivudine resistant HBV strain and relevance in the outcome of a OLT patient [abstract no. 2285]. Hepatology 1998 Oct; 28 (4 Pt 2): 734A
64. 64. Ben Ari Z, Pappo O, Mor E, et al. Lamivudine resistance in recurrent hepatitis B virus after orthotopic liver transplantation [abstract no. 2279]. Hepatology 1998 Oct; 28 (4 Pt 2): 732A
65. 65. Da Silva L, Pinho JRR, Sitnik R, et al. Virologic factors associated with non response to lamivudine (LAM) and viral mutations associated with drug resistance in Brazilian patients with chronic hepatitis B (CHB) [abstract no. 2256]. Hepatology 1998 Oct; 28 (4 Pt 2): 726A
66. 66. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with lamivudine resistance in human immunodeficiency virus (HIV)-infected patients [abstract no. 1291]. Hepatology 1998 Oct; 28 (4 Pt 2): 485A
67. 67. Petit MA, Buffello D, Roche B, et al. Characterization of new hepatitis B virus (HBV) variants emerging from patients sequentially treated with antiviral therapies and lamivudine for recurrent hepatitis B after liver transplantation [abstract no. 1700]. Hepatology 1998 Oct; 28 (4 Pt 2): 587A
68. 68. Gutfreund KS, Fischer KP, Bain VG, et al. Genotypic succession of mutations of the HBV polymerase associated with lamivudine resistance in chronic hepatitis B and liver transplantation [abstract no. 1297]. Hepatology 1998 Oct; 28 (4 Pt 2): 487A
69. 69. Jaeckel E, Tillman HL, Krueger M, et al. Resistance against nucleoside analogues in patients after liver transplantation for hepatitis B cirrhosis [abstract no. 289]. Hepatology 1998 Oct; 28 (4 Pt 2): 235A
70. 70. Fontaine H, Thiers V, Zylberberg H, et al. HBV resistances lamivudine according to daily dosage and immune status [abstract no. 218]. Hepatology 1998 Oct; 28 (4 Pt 2): 217A
71. 71. Gutfreund KS, Addison WR, Williams M, et al. HBV recurrence in chronic hepatitis B treated with lamivudine after prolonged seroconversion and long term treatment with lamivudine [abstract no. 1298]. Hepatology 1998 Oct; 28 (4 Pt 2): 487A
72. 72. Santantonio T, Mazzola M, Miglietta A, et al. Long term efficacy of lamivudine treatment in chronic anti-HBe positive hepatitis B [abstract no. P/C06/105]. J Hepatol 1999; 30 Suppl. 1: 140
73. 73. Minamitani S, Nishiguchi S, Tamori A, et al. Estimation of lamivudine treatment in Japanese patients with chronic hepatitis B virus infection [abstract no. 2246]. Hepatology 1998 Oct; 28 (4 Pt 2): 724A
74. 74. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-6
75. 75. Fujioka S-i, Shimomura H, Fujio K, et al. Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long term therapy. Hepatology Res 1999; 13: 97-104
76. 76. McCaughan G, Koorey D, Spencer J, et al. Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss [abstract no. 402]. Hepatolopy 1998 Oct; 28 (4 Pt 2): 263A
77. 77. Dodson SF, Balan V, Shakil O, et al. Lack of efficacy of lamivudine for HBV infection after liver transplantation [abstract no. 398]. Hepatology 1998 Oct; 28 (4 Pt 2): 262A
78. 78. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-8
79. 79. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 1032-5
80. 80. Yao G. YMDD mutation in Chinese patients following lamivudine therapy for chronic hepatitis B infection [abstract no. G3689]. Gastroenterology 1999 Apr; 116 (4 Pt 2): A848-9
81. 81. Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famiciclovir and lamivudine. Int Antiviral News 1997 Aug; 5: 123-4
82. 82. Locamini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 21: 294-7
83. 83. Gaillard RK, Allen MI, Miller WH, et al. In vitro evaluation of potential add-on therapeutics for the treatment of lamivudine treated patients infected with YMDD mutant HBV [abstract no. 624]. Hepatology 1998 Oct; 28 (4 Pt 2): 318A
84. 84. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73
85. 85. Perrillo R, Schiff E, Magill A, et al. In vivo demonstration of sensitivity of YMDD variants to adefovir [abstract no. P/C06/035]. J Hepatol 1999; 30 Suppl. 1: 122
86. 86. Gibbs CS, Westland CW, Yang H, et al. In vitro analysis of cross-resistance profiles of new antivirals for chronic HBV infection [abstract no. WP1/06]. J Hepatol 1999; 30 Suppl. 1:62
87. 87. Walters K, Tipples G, Allen MI, et al. Generation of stable lamivudine-resistant hepatitis B virus cell lines for antiviral screening [abstract no. 1706]. Hepatology 1998 Oct; 28 (4 Pt 2): 589A
88. 88. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998 Feb; 27: 628-33
89. 89. Torresi J, Silveira LE, Chin R, et al. Replicative fitness of hepatitis B virus variants selected by antiviral nucleoside analogues [abstract no. P/C05/011]. J Hepatol 1999; 30 Suppl. 1: 108
90. 90. Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [abstract no. 625]. Hepatology 1998 Oct; 28 (4 Pt 2): 319A
91. 91. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29: 939-45
92. 92. Zhu Y-L, Dutschman GK, Liu S-H, et al. Anti-hepatitis B virus activity and metabolism of 2′,3′ dideoxy-2′,3′-didehydro-β-L(-)-5-fluorocytidine. Antimicrob Agents Chemother 1998; 42 (7): 1805-10
93. 93. Cui L, Schinazi RF, Gosselin G, et al. Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells: implications for predicting drug hepatotoxicity. Biochem Pharmacol 1996 Nov 22; 52: 1577-84
94. 94. Cui L, Locatelli L, Xie M-Y, et al. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther 1997 Mar; 280: 1228-34
95. 95. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992; 43: 2059-64
96. 96. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992 Aug; 36: 1688-94
97. 97. Gray NM, Marr CLP, Penn CR, et al. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ. Biochem Pharmacol 1995; 50 (7): 1043-51
98. 98. Honkoop P, de MRA, Scholte HR, et al. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997 Jul; 26: 211-5
99. 99. Schalm SW, de Man RA, Heijtink RA, et al. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995; 22 Suppl. 1: 52-6
100. 100. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-105
101. 101. Swartz MN. Mitochondrial toxicity - new adverse drug effects [editorial]. N Engl J Med 1995; 333: 1146-8
102. 102. Cui L, Yoon S, Schinazi RF, et al. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555-63
103. 103. Chen C-H, Cheng Y-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989 Jul 15; 264 (20): 11934-7
104. 104. Chen C-H, Vazquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-8
105. 105. Chariot P, Drogou I, Lacroix-Szmania, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60
106. 106. Koziel MJ. What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B. Hepatology 1999; 29: 1331-3
107. 107. Schlaak JF, Tully G, Löhr HF, et al. The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. Hepatology 1999; 30: 353-8
108. 108. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75
109. 109. Marinos G, Vaoumov NV, Williams R. Impact of cellular inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996 Nov; 24: 991-5
110. 110. Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995 Dec; 35: 1174-80
111. 111. Angel JB, Hussey EK, Hall ST, et al. Pharmacokinetics of 3TC (GR 109714X) administered with and without food to HIV-infected patients. Drug Invest 1993 Aug; 6: 70-4
112. 112. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33
113. 113. Sokal E, Roberts EA, Micli-Vergani d, et al. Dose-finding and safety of lamivudine (LAM) in children and adolescents with chronic hepatitis B [abstract no. 1306]. Hepatology 1998 Oct; 28 (4 Pt 2): 489a
114. 114. van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992 Dec; 6: 1471-5
115. 115. Johnson MA, Verpooten GA, Daniel MJ, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998; 46: 21-7
116. 116. Glaxo Wellcome Inc. Epivir-HBV (lamivudine) product information. Glaxo Wellcome Inc., Research Triangle Park, North Caroline, USA, Dec, 1998
117. 117. Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 1998; 54: 363-6
118. 118. Shibata H, Hoshino Y, Shimizu M, et al. Comparison of pharmacokinetics of lamivudine between elderly volunteers and healthy young male volunteers [in Japanese]. Kinsho Iyaku 1997; 13; (21): 5451-64
119. 119. Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923-9
120. 120. Moore KHP, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996 May; 59: 550-8
121. 121. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997 Apr; 53: 657-80
122. 122. Dienstag J, Schiff E, Wright T, et al. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis BE-antigen (HReAg) seroconversion [abstract no. L0148]. Gastroenterology 1998 Apr 15; 114 (Pt 2): A1235
123. 123. Tanikawa K, Hayashi N, Ichida F, et al. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [abstract no. 521]. Hepatology 1997; 26 (4 Pt 2): 259A
124. 124. Yao G, Wang B, Cui Z, et al. Long term efficacy of lamivudine in the treatment of patients with chronic hepatitis B virus infection - a multicenter randomised, double-blind, placebo controlled trial [abstract no. G3688]. Gastroenterology 1999 Apr; 116 (4 Pt 2) PT 2: A848
125. 125. Schiff E, Karayalcin S, Grimm I, et al. A placebo-controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract no. 901]. Hepatology 1998 Oct; 28 (4 Pt 2): 388a
126. 126. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96
127. 127. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996 Nov 27; 62: 1456-62
128. 128. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 Nov 2; 348: 1212-5
129. 129. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9
130. 130. Van-Thiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997 May-Jun; 44: 808-12
131. 131. Terrauli NA, Wright TL, Roberts JP, et al. Combined short term hepatitis B immunoglobulin (HBIG) and long term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients [abstract no. 905]. Hepatology 1998 Oct; 28 (4 Pt 2): 389a
132. 132. Dodson SF, Ballan V, Shakil O, et al. Combination HBIG and lamivudine after liver transplantation for hepatitis B related liver disease [abstract no. 2283]. Hepatology 1998 Oct; 28 (4 Pt 2): 733A
133. 133. Yao F, Osorio R, Roberts J, et al. Intramuscular hepatitis B immune globulin combined with oral lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation [abstract no. 391]. Hepatology 1998 Oct; 28 (4 Pt 2): 260A
134. 134. Marzano A, Debernardi-Venon W, Actis GC, et al. Efficacy of lamivudine treatment associated with low-dose immunoprophylaxis on HBV recurrence after liver transplantation [abstract no. P/C01/030]. J Hepatol 1999; 30 Suppl. 1: 80
135. 135. Han S-H, Martin P, Markowitz J, et al. Long term combination HBIG and lamivudine is highly effective in preventing recurrent hepatitis B in orthotopic liver transplant (OLT) recipients [abstract no. 238]. Hepatology 1998 Oct; 28 (4 Pt 2): 222A
136. 136. Roche B, Samuel D, Roque AM, et al. Intravenous anti-HBs Ig combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation [abstract no. P/C01/032]. J Hepatol 1999; 30 Suppl. 1: 80
137. 137. Gil H, Vuitton D-A, Rozenbaum A, et al. Efficacité de la lamivudine sur la réplication du virus de l'hépatite B chez un malade atteint de syndrome d'immunodéficience acquise. Gastroenterol Clin Biol 1997 Dec; 21: 997-8
138. 138. Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type I. Clin Infect Dis 1996 Sep; 23: 638-9
139. 139. Sinclair FJ, Womack M, Illeman M, et al. Benefits and safety of lamivudine (3TC) therapy in HIV positive patients with chronic hepatitis B or C [abstract]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver. Vol 1: 287
140. 140. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996 Nov 1; 125: 705-12
141. 141. Schiano TD, Lissoos TW, Ahmed A, et al. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol 1997 Sep; 92: 1563-4
142. 142. Cooper D, Dore G, Goh L. Effect of lamivudine on hepatitis B/ HIV co-infected patients from the CAESAR Study [abstract no. H-31]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28-Oct 1; Toronto, 219
143. 143. Raffi F, Hoff J, Sadr FB, et al. HBs seroconversion of a precore hepatitis B virus mutant infection with lamivudine-containing anti-HIV regimen [abstract no. 32118]. Abstracts of the 12th World AIDS Conference 1998, 28 Jun 28-Jul 3; Geneva, 544
144. 144. Tsertsvadze T, Gochitashvili N, Sharvadze L, et al. Efficiency of lamivudine in patients with HIV and HBV co-infection [abstract no. P251]. AIDS 1998; 12 Suppl. 4: S80
145. 145. Bernabeu-Wittel M, Leo E, Herrera JM, et al. Hepatitis B virus replication decreases in HIV-coinfected patients treated with lamivudine [abstract no. 2245]. Hepatology 1998 Oct; 28 (4 Pt 2): 724A
146. 146. Nagai K, Hosaka H, Kubo S, et al. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. J Gastroenterol 1999; 34: 275-81
147. 147. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin [abstract]. Hepatology 1997 Oct; 26 Pt 2: 152
148. 148. Tillmann HL, Trautwein C, Krilger M, et al. Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation [abstract]. J Hepatol 1997; 26 Suppl. 1: 153
149. 149. Belli LS, Alberti AB, Silini E, et al. Lamivudine for prophylaxis and treatment of hepatitis B after liver transplantation [abstract]. J Hepatol 1997; 26 Suppl. 1: 153
150. 150. Markowitz J, Pakrasi A, Hollis P, et al. Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients [abstract]. Hepatology 1996 Oct; 24 Pt 2: 182
151. 151. Tillmann HL, Böker K, Trautwein C, et al. Lamivudine in patients not responding to famciclovir for recurrent hepatitis B after liver transplantation [abstract]. J Hepatol 1996; 25 Suppl. 1: 129
152. 152. Ben-Ari Z, Shmueli D, Mor E, et al. Beneficial effect of lamivudine pre-and post-liver transplantation for hepatitis B infection. Transplant Proc 1997 Sep; 29: 2687-8
153. 153. Proenza J, Friedenberg F, Rothstein K, et al. Lumivudine treatment of chronic hepatitis B and post-liver transplant for fulminant hepatitis B [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1362
154. 154. Bartholomew M, Vicary C, Roach K, et al. Use of lamivudine in the treatment of recurrent hepatitis B infection post-liver transplantation. Gastroenterology 1995 Apr; 108 Suppl.: A1030
155. 155. Woolf GM, Wagner DA, Petrovic LM, et al. Quantitative liver function (QLF) testing during lamivudine (L) therapy of fibrosing cholestatic hepatitis (FCH) due to recurrent hepatitis B virus (HBV) after liver transplantation (LT). Hepatology 1996 Oct; 24 (Pt 2): 599
156. 156. Herrero JI, Quiroga J, Sangro B, et al. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig Dis Sci 1998; 43 (6): 1186-9
157. 157. Ben-Ari Z, Shmeli D, Mor E, et al. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Trans plantation 1997; 63: 393-6
158. 158. Campo N, Dardano G, Caglieris S, et al. Efficacy of lamivudine therapy in patients with HBV related liver disease [abstract no. C06/040]. J Hepatol 1998; 28 Suppl. 1: 195
159. 159. Jochum C, Holtmann G, Hoffmann R, et al. Ganciclovir and lamivudine combination therapy after orthotopic liver transplantation [abstract no. L0279]. Gastroenterology 1998 Apr 15; 114 (4 Pt 2): A1266
160. 160. Nery JR, Magill A, Lavandara R, et al. Evolution of prevention and treatment of post-liver transplant HBV recurrence [abstract no. 186]. Transplantation 1998 Jun 27; 65: S49
161. 161. Jaeckel E, Tillmann HL, Krueger M, et al. Prolonged therapy of recurrent hepatitis B infection after liver transplantation with nucleoside analogues [abstract no. P/C06/031]. J Hepatol 1998; 28 Suppl. 1: 115
162. 162. Jaeckel E, Tillman HL, Krueger M, et al. Outcome of hepatitis B/D reinfection after liver transplantation under nucleoside analogue therapy [abstract no. C06/039]. J Hepatol 1998; 28 Suppl. 1: 195
163. 163. Priclo M, Córdoba J, Rayon JM, et al. Good response to lam ivudine therapy in patients with de novo hepatitis B following orthotopic liver transplantation: a pilot study [abstract no. 741]. Hepatology 1998 Oct; 28 (4 Pt 2): 348a
164. 164. Andreone P, Caraceni P, Grazi GL, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 20: 985-9
165. 165. Morgan G, Diflo T, John D, et al. Recurrent hepatitis B: predictors and prophylaxis following liver transplantation [abstract no. 2281]. Hepatology 1998 Oct; 28 (4 Pt 2): 733A
166. 166. Caraceni P, Grazi GL, Belli L, et al. Long term follow-up of lamivudine treatment for acute hepatitis B after liver transplantation [abstract no. 732]. Hepatology 1998 Oct; 28 (4 Pt 2): 345A
167. 167. Roche B, Samuel D, Roque AM, et al. Lamivudine therapy for HBV infection after liver transplantation [abstract no. P/C01/022]. Hepatology 1999; 30 Suppl. 1: 78
168. 168. Marzano A, Debernardi-Venon W, Actis GC, et al. Antiviral therapy fur HBV recurrence after liver transplantation [abstract no. C01/010]. J Hepatol 1999; 30 Suppl. 1: 171
169. 169. Crespo J, Fäbrega E, Casafont F, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5: 175-83
170. 170. Rostaing L, Henry S, Cisterne J-M, et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadavcric renal transplantation. Transplantation 1997 Dec 15; 64: 1624-7
171. 171. Chossegros P, Gamier JL, Daoud A, et al. After kidney transplantation, lumivudine drastically modifies chronic B hepatitis evolution [abstract]. J Hepatol 1997; 26 Suppl. 1: 206
172. 172. Al Faraidy K, Yoshida EM, Davis JE, et al. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Trans plantation 1997 Sep 27; 64: 926-8
173. 173. Chan T-M, Wu P-C, Li F-K, et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177-81
174. 174. Brind AM, Bennett MK, Bassendine MF. Nucleoside analogue therapy in fibrosing cholestatic hepatitis - a case report in an HBsAg positive renal transplant patient. Liver 1998; 18: 134-9
175. 175. Jung YO, Lee YS, Yang WS, et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplanta tion 1998; 66: 733-7
176. 176. Wong WW, Ma MM, Bain VG. Treatment of immunosuppression-related HBV exacerbation with lamivudine [abstract no. 2251]. Hepatology 1998; 28 (4 Pt 2): 725A
177. 177. Picardi M, Selleri C, De Rosa G, et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 1267-9
178. 178. Silvestri F, Fanin R, Sperotto A, et al. Lamivudine for the prevention of hepatitis B virus (HBV) reactivation during autologous stem cell (SC) transplantation: a case report [abstract no. 4460]. Blood 1998 Nov 15; 92 (Pt 2) Suppl. 1: 338b
179. 179. Clark FL, Drummond MW, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998 Apr; 9: 385-7
180. 180. ter Borg F, Smorenburg S, de Man RA, et al. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 2267-70
181. 181. Ahmed A, Keefe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249-51
182. 182. Günther S, von Breunig F, Santantonio T, et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30: 749-54
183. 183. Pichoud C, Seignéres B, Wang Z, et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230-7
184. 184. Bonham CA, Dodson SF, Rakela J, et al. Use of hepatic allografts with antibodies to hepatitis B virus in nonimmune recipients [abstract no. 743]. Hepatology 1998 Oct; 28 (4 Pt 2): 348A
185. 185. Sponseller CA, Smith-Wilkaitis N, Bacon BR, et al. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine [abstract no. 1708]. Hepatology 1998 Oct; 28 (4 Pt 2): 589A
186. 186. Rudd JN, Al-Haddadin D. Possible role for hepatitis B vaccine after lamivudine rescue for severe acute hepatitis B [abstract no. L0390]. Gastroenterology 1999 Apr; 116 (4 Pt 2): A1268
187. 187. Santantonio T, Mazzola M, Pastore G. Lamivudine is safe and effective in fulminant hepatitis B. J Hepatol 1999; 30: 551
188. 188. Yoshiba M, Sekiyama K, Inoue K. Treatment of hepatitis in fulminant viral hepatitis [abstract no. 2347]. Hepatology 1998 Oct; 28 (4 Pt 2): 749A
189. 189. Rosei MA, Rapicetta M, Argentini C, et al. Favourable outcome of an acute hepatitis caused by a putative fulminant HBeAg negative variant of HBV by early treatment with lamivudine [abstract no. C06/142]. J Hepatol 1999; 30 Suppl. 1: 265
190. 190. Hassanein T, Hart ME, Monson P, et al. Lamivudine improves the cholestatic phase of acute hepatitis B infection [abstract no. 2257]. Hepatology 1998; 28 (4 Pt 2): 727A
191. 191. Heathcote J, Schalm SW, Cianciara J, et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection [abstract no. GS2/07]. J Hepatol 1998; 28 Suppl. 1:43
192. 192. Honkoop P, Deman RA, Zondervan PE, et al. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997 Apr; 17: 103-6
193. 193. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
194. 194. Callea F, Baronchelli C, Rodolfi A, et al. Histopathology of chronic viral hepatitis: guidelines for a revised classification. Ital J Gastroenterol 1995; 27: 137-40
195. 195. Kapke GF, Watson G, Sheffler S, et al. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. J Viral Hepatitis 1997; 4: 67-75
196. 196. Krajden M, Minor J, Cork L, et al. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J Viral Hepatitis 1998; 5: 415-22
197. 197. Pawlotsky J-M, Bastie A, Lonjon I, et al. What technique should be used for routine detection and quantification of HBV DNA in clinical samples. J Virol Methods 1997; 65: 245-53
198. 198. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997 Oct; 113: 1258-63
199. 199. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 Dec 21; 333: 1657-61
200. 200. Liaw YF, Chien RN, Sheen IS. et al. A randomized, controlled, dose-ranging study of lamivudine in patients with chronic hepatitis B [abstract]. J Gastroenterol Hepatol 1995; 10 Suppl. 3: A68
201. 201. Lai C-l, Ching C-k, Tung AK-m, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997 Jan; 25: 241-4
202. 202. de Man RA, Schalm SW, Main J, et al. A dose ranging study to determine the antiviral activity and safety of lamivudine (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection [abstract]. Gut 1993; 34 (4) Suppl.: S5
203. 203. Tanikawa K, Anti-HBV activity of lamivudine in Japanese. Hepatology 1996; 23: 1-33
204. 204. Honkoop P, de Man RA, Niesters HGM, et al. Quantitative hepatitis B virus DNA assessment by the limiting dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatitis 1998; 5: 307-12
205. 205. Wolters LMM, Niesters HGM, Schalm SW, et al. Hepatitis B viral dynamics during four weeks of lamivudine: 150 mg versus 600 mg [abstract]. Eur J Gastroenterol Hepatol 1998 Dec; 10 (12): A89
206. 206. Kim JW, Lee MY, Chin YJ, et al. Interferon alpha versus interferon alpha and lamivudine in the treatment of chronic active hepatitis B [abstract]. VIII International Symposium on Viral Hepatitis; 1988 Jan 22-24; Madrid, 121
207. 207. Laras A, Koskinas J, Avgidis K, et al. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241-8
208. 208. Visco G, Nicastri E, Longo MA. Eficacy of lamivudine (3TC) plus alpha-interferon (IFN) on replication of hepatitis B virus (HRV) in chronic active hepatitis B (CAH/B) patients (pts) previously unresponsive to IFN alone: an open pilot study [abstract]. VIII International Symposium on Viral Hepatitis; 1988 Jan 22-24; Madrid, 122
209. 209. Kim JW, Lee MY, Chin YJ, et al. Lamivudine therapy for hepatitis B virus-related decompensated cirrhosis [abstract]. VIII International Symposium on Viral Hepatitis; 1998 Jan 22-24; Madrid, 123
210. 210. Choo KR, Lee YS, Lee KC, et al. Lamivudine rescue from the accelerating course of chronic hepatitis B [abstract]. VIII International Symposium on Viral Hepatitis; 1998 Jan 22-24; Madrid, 124
211. 211. Mutimer D, Tang H, Dragon B, et al. Antiviral treatment of hepatitis B virus infected patients: evaluation of response using a sensitive quantitative polymerase chain reaction assay [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1341
212. 212. Van Thiel DM, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced decompensated liver disease due to hepatitis B [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1407
213. 213. Honkoop P, de MRA, Heijtink RA. Hepatitis B reactivation after lamivudine. Lancet 1995 Oct 28; 346: 1156-7
214. 214. Leung YK, So T. Treatment of chronic hepatitis B using thymosin alpha 1 and a combination of two nucleoside analogs, lamivudine and famciclovir [abstract no. 215]. Hepatology 1998 Oct; 28 (4 Pt 2): 216a
215. 215. Donada C., Piva S, Faelli A, et al. Interferon alfa and lamivudine in patients with chronic hepatitis B anti-HBe positive [abstract no. C06/068]. J Hepatol 1999; 30 Suppl. 1: 246
216. 216. Jaboli MF, Marchetto S, Fabbri C, et al. The efficacy and safety of administration of lamivudine plus α-interferon in patients with chronic hepatitis B [abstract no. C06/076]. J Hepatol 1999; 30 Suppl. 1: 248
217. 217. Hann H-WL, Clayton MM, Feitelson MA. Evaluation of HBxAg/anti-HBx in lamivudine treated hepatitis B patients [abstract no. 2250]. Hepatology 1998 Oct; 28 (4 Pt 2): 725A
218. 218. Amarapurkar DN, Chauhan S, Agal S, et al. Combination therapy of low-dose interferon and lamivudine for chronic hepatitis B [abstract no. 211]. Hepatology 1998 Oct; 28 (4 Pt 2): 215A
219. 219. Akarca US, Yilmaz M, Ersoz G, et al. Interferon plus lamivudine therapy for patients with chronic hepatitis B with and without HBeAg who relapsed after interferon treatment [abstract no. P/C06/087]. J Hepatol 1999; 30 Suppl. 1: 135
220. 220. Hong S-P, Kwon CI, Oh J, et al. Lamivudine maintenance therapy in patients of chronic B viral hepatitis [abstract no. G3205]. Gastroenterology 1999 Apr; 116 (4 Pt 2): A738
221. 221. Purow JM, Weisz K, Eison RC, et al. Combination therapy of hepatitis B with lamivudine and famciclovir [abstract no. G3470]. Gastroenterology 1999 Apr; 116 (4 Pt 2): A800
222. 222. Liaw YF, Lai CL, Leung NWY, et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo-controlled multicentre study in Asia [abstract no. L0375]. Gastroenterology 1998 Apr 15; 114 Pt 2: A1289
223. 223. Leung N, Wu PC, Tsang S, et al. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine [abstract no. 1307]. Hepatology 1998 Oct; 28 (4 Pt 2): 489a
224. 224. Leung NWY, Lai CL, Chang TT, et al. Three year lamivudine therapy in chronic HBV [abstract no. GS5/25]. J Hepatol 1999; 30 Suppl. 1: 59
225. 225. Goodman Z, Dhillon AP, Wu PC, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B [abstract no. GS5/26]. J Hepatol 1999; 30 Suppl. 1: 59
226. 226. Schiff E, Cianciara J, Kowdley K, et al. Durability of HBEAG seroconversion after lamivudine monotherapy in controlled phase II and III trials [abstract no. 1]. Hepatology 1998 Oct; 28 (4 Pt 2): 163A
227. 227. Drunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-50
228. 228. Zhang X, Zoulim F, Habersetzer F, et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8-16
229. 229. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B [abstract no. P/C06/015]. J Hepatol 1999; 30 Suppl. 1: 117
230. 230. Alexopoulou A, Zafiropoulou R, Papakonstantinou A, et al. Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with interferon: evaluation of long term efficacy [abstract no. 1312]. Hepatology 1998 Oct; 28 (4 Pt 2): 490a
231. 231. Chatterton ML, Brown M, Gray F, et al. The effect of lamivudine and interferon alpha-2B (IFNα) on work productivity in patients with chronic hepatitis B (CHB) infection [abstract no. 1308]. Hepatology 1998 Oct; 28 (4 Pt 2): 489a
232. 232. Lai CL, Yuen MF, Cheng CC, et al. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection [abstract no. 1311]. Hepatology 1998 Oct; 28 (4 Pt 2): 490A
233. 233. Tibbs CJ, Williams R. Liver transplantation for acute and chronic viral hepatitis. J Viral Hepatitis 1995; 2: 65-72
234. 234. Muller R, Samuel D, Fassati LR, et al. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. J Hepatol 1994; 21: 1140-3
235. 235. Yoshida EM. Hepatitis B infection and liver transplantation. Can J Gastroenterol 1997 Jul-Aug; 11: 462-8
236. 236. O'Grady J, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992; 14: 104-11
237. 237. Debernardi W, Venon A, Marzano A, et al. Antiviral prophylaxis with nucleoside analogues can reduce the hepatitis B recurrence after liver transplantation [abstract]. J Hepatol 1997; 26 Suppl. 1: 145
238. 238. Mutimer D, Tang H, Dragon B, et al. Lamivudine (LAM) treatment for hepatitis B virus (HBV) infected patients undergoing liver transplantation (LT): monitoring response with a quantitative polymerase chain reaction (QPCR) assay [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1342
239. 239. Naoumov NV, Lopes R, Crepaldi G, et al. Randomised trial of lamivudine (LAM) versus hepatitis B immunoglobulin (HBIG) for prophylaxis of HBV recurrence after liver transplantation [abstract no. GS1/02]. J Hepatol 1999; 30 Suppl. 1: 51
240. 240. Dodson SF, Balan V, Shakil O, et al. Substitution of lamivudine for long term HBIG after liver transplantation for hepatitis B related liver disease [abstract no. 399]. Hepatology 1998 Oct; 28 (4 Pt 2): 262A
241. 241. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997 May 17; 349: 1413-21
242. 242. Leung N, Dienstag J, Schiff E, et al. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients [abstract no. 1698]. Hepatology 1998 Oct; 28 (4 Pt 2): 587A
243. 243. Glaxo Wellcome Inc. Epivir (lamivudine) prescribing information. Glaxo Wellcome Inc. Research Triangle Park, North Carolina, USA, Dec, 1997
244. 244. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1996; 16: 31-41
245. 245. World Health Organization. Executive Summary: The World Health Report 1998: Life in the 21st century - a vision for all [on line]. [Accessed 1999, May 26]. World Health Organization. Available from: URL: http://www.oms.ch/whr/1998/ exsum98e.htm
246. 246. Wong JB, Koff RS, Tinè F, et al. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
247. 247. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50
248. 248. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8
249. 249. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999; 340: 798-9
250. 250. World Health Organization. The World Health Report 1998: life in the 21st century: a vision for all. Report of the Director General. Geneva: World Health Organization, 1998
251. 251. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997 Jan 16; 336: 196-203
252. 252. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New Engl J Med 1997; 336: 1855-9
253. 253. Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997; 336: 1906-7
254. 254. World Health Organization. Fifty facts from the World Health Report 1998 [on time]. [Accessed 1999, May 26]. World Health Organization. Available from: URL: http://www. who.int/whr/1998/factse.htm
255. 255. Camma C, Giunta M, Almasio P. Interferon for chronic hepatitis B: a meta-analysis of randomized controlled trials [abstract no. P/C06/018]. J Hepatol 1999; 30 Suppl. 1: 118
256. 256. Honkoop P, Hansen BE, Ashruf RZ, et al. Long term follow-up of chronic hepatitis B patients after interferon treatment [abstract no. P/C06/019]. J Hepatol 1998; 28 Suppl. 1:112
257. 257. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23
258. 258. Niederau C, Heintges T, Lange S, et al. Long term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7
259. 259. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 1863-73
260. 260. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93 (6): 896-900
261. 261. Hoofnagle JH, Di BAM. The treatment of chronic viral hepatitis. N Engl J Med 1997 Jan 30; 336: 347-56
262. 262. Brumage LK, Wright TL. Treatment for recurrent viral hepatitis after liver transplantation. J Hepatol 1997 Feb; 26: 440-5
263. 263. Perrillo RP. Treatment of posttransplantation hepatitis B. Liver Transpl Surg 1997; 3 Suppl. 1: S8-12
264. 264. Terrault NA, Wright TL. Hepatitis B virus infection and liver transplantation. Gut 1997 May; 40: 568-71
265. 265. Rostaing L, Modesto A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-6
266. 266. Munoz de Bustillo E, Ibarrola C, Andres A, et al. Hepatitis-B-virus-related fibrosing, cholestatic hepatitis after renal transplantation with acute graft failure following interferon-α therapy. Nephrol Dial Transplant 1998; 13: 1574-6
267. 267. de Jongh FE, Janssen HLA, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5
268. 268. Lok ASF, Lai C-L, Wu P-C, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-43
269. 269. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepaitis type B. Hepatology 1986; 6 (2): 167-72
270. 270. Sampliner RE, Hamilton FA, Iseri OA, et al. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci 1979; 277 (1): 17-22
271. 271. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-7
272. 272. Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co infection as the significant determinants of long term prognosis. J Hepatol 1990; 30: 706-14
273. 273. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117 (10): 837-8
274. 274. Rustgi VK, Hoofnagle JH, Gerin JL, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101: 795-7
275. 275. Davaro RE, Cheeseman SH, Keroack MA, et al. The significance of isolated antibody to hepatitis B core antigen seropositivity in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 189-90
276. 276. Saillour F, Dabis F, Dupon M, et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. BMJ 1996; 313: 461-4
277. 277. Gilson RJC, Hawkins AE, Beccham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 507-606
278. 278. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30: 536-50
279. 279. Dusheiko G. A pill a day, or two, for hepatitis B? Lancet 1999 Mar 27; 353 (9158): 1032-3